Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Non-Muscle Invasive Bladder Neoplasms 2Urinary Bladder Neoplasms 1

Interventions

Docetaxel 77Radiotherapy 73Prednisone 66Leuprolide 51Goserelin 49Gemcitabine 49Cisplatin 48bicalutamide 46enzalutamide 43Androgen Antagonists 36pembrolizumab 32Abiraterone Acetate 31Mitomycin 29acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 28Magnetic Resonance Spectroscopy 28Carboplatin 27Flutamide 25Nivolumab 24Triptorelin Pamoate 23Sunitinib 23apalutamide 22Radiation 22Doxorubicin 20darolutamide 19abiraterone 18Gonadotropin-Releasing Hormone 18cabozantinib 17atezolizumab 16Specimen Handling 16Radiosurgery 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × VB4-845 × Genitourinary × Clear all
NCT02449239 2023-07-24

VISTA

Sesen Bio, Inc.

Phase 3 Completed
133 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04859751 2021-04-26

Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer

Qilu Pharmaceutical Co., Ltd.

Phase 3 Unknown
53 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡